SCHEMBL1241301

SCHEMBL1241301

COCCNCc1ccc(Br)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.62
CYP1A2 P05177 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C19 P33261 1/20 0.56
LMNA P02545 1/20 0.54
KDM4E B2RXH2 2/20 0.54
GLA P06280 1/20 0.54
PYCR1 P32322 1/20 0.52
HTR2A P28223 2/20 0.51
MAPT P10636 2/20 0.49
ALDH1A1 P00352 1/20 0.49
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
GAA P10253 1/20 0.46
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA4 P22748 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29602871 0.83 TAAR1 (0.55) L3MBTL1KDM4EGLAHTR2AMAPT
SCHEMBL8252520 0.82 L3MBTL1 (0.64) L3MBTL1LMNAKDM4EALDH1A1MEN1
SCHEMBL12317 0.82 L3MBTL1 (0.64) L3MBTL1LMNAHTR2AALDH1A1MEN1
SCHEMBL23124725 0.81 CYP1A2 (0.57) L3MBTL1CYP1A2CYP2D6CYP2C19LMNA
SCHEMBL9156034 0.81 L3MBTL1 (0.62) L3MBTL1KDM4EALDH1A1MEN1KMT2A
SCHEMBL2312495 0.81 CHRM2 (0.68) L3MBTL1LMNAKDM4EHTR2AALDH1A1
SCHEMBL6325754 0.81 L3MBTL1 (0.67) L3MBTL1KDM4EHTR2AMEN1KMT2A
SCHEMBL2051245 0.81 L3MBTL1 (0.62) L3MBTL1KDM4EMAPTALDH1A1MEN1
SCHEMBL11304095 0.81 L3MBTL1 (0.67) L3MBTL1LMNAKDM4EHTR2AALDH1A1
SCHEMBL556793 0.80 MEN1 (0.64) L3MBTL1MAPTMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025133098-A2 PROCESSES TO MAKE CRYSTALLINE FORMS OF (S)-N-(3-AMINO-1-(HYDROXYAMINO)-3-METHYL-1-OXOBUTAN-2-YL)-4- ((4-(((2-METHOXYETHYL)AMINO)METHYL)PHENYL)ETHYNYL)BENZAMIDE SALTS INTERVET INTERNATIONAL B.V. (NL) 2025-06-26 WO claimed
WO-2025133098-A2 PROCESSES TO MAKE CRYSTALLINE FORMS OF (S)-N-(3-AMINO-1-(HYDROXYAMINO)-3-METHYL-1-OXOBUTAN-2-YL)-4- ((4-(((2-METHOXYETHYL)AMINO)METHYL)PHENYL)ETHYNYL)BENZAMIDE SALTS INTERVET INTERNATIONAL B.V. (NL) 2025-06-26 WO disclosed
WO-2025133088-A1 CRYSTALLINE FORMS OF(S)-N-(3-AMINO-1-(HYDROXYAMINO)-3-METHYL-1-OXOBUTAN-2-YL)-4- ((4-(((2-METHOXYETHYL)AMINO)METHYL)PHENYL)ETHYNYL)BENZAMIDE SALTS INTERVET INTERNATIONAL B.V. (NL) 2025-06-26 WO disclosed
US-7879808-B2 potent activity against resistant pneumococci; for treating domestic fowl MEIJI SEIKA KAISHA, LTD. (JP) 2011-02-01 US disclosed
US-20100210570-A1 LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT MEIJI SEIKA KAISHA LTD. (JP) 2010-08-19 US disclosed
EP-2151447-A1 LINCOMYCIN DERIVATIVES AND ANTIBACTERIAL AGENTS CONTAINING THE SAME AS THE ACTIVE INGREDIENT Meiji Seika Kaisha Ltd. (JP) 2010-02-10 EP disclosed
US-20100029754-A1 THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 ASTRAZENECA AB (SW) 2010-02-04 US disclosed
US-7572826-B2 Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme IKK-2 ASTRAZENECA AB (SE) 2009-08-11 US disclosed
US-20060058522-A1 Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 ASTRAZENECA AB (SE) 2006-03-16 US disclosed
EP-1583755-A1 THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZIME IKK-2 AstraZeneca AB (SE) 2005-10-12 EP disclosed
WO-2004063186-A1 THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZIME IKK-2 ASTRAZENECA AB (SE) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058522-A1 Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 NFKBIA, RELA, IKBKE L3MBTL1 3153/4885CYP1A2 355/4885CYP2D6 819/4885
US-20100210570-A1 LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT LAS1L, LCLAT1, LYPLA1 L3MBTL1 24/4885CYP1A2 2117/4885CYP2D6 785/4885
US-20100029754-A1 THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 NFKBIA, RELA, IKBKE L3MBTL1 3153/4885CYP1A2 355/4885CYP2D6 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.